Xiangshu Xiao, PhD

Xiao2

Primary Affiliation

Associate Professor, Physiology and Pharmacology

Program Affiliation

Physiology & Pharmacology

Cancer Biology

Program in Molecular & Cellular Biosciences

Background & Education

Postdoc 2007, UT Southwestern Medical Center, Dallas, TX

Ph.D. 2005, Purdue University, West Lafayette, IN

M.Sc. 2001, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai

B.S. 1998, Beijing Medical University

Research

Cancer chemical biology.  Please go here for more details.

Meet the Lab

Useful Links

Publications 
Selected Publications

1. Xie, F.;Li, B. X.;Kassenbrock, A.;Xue, C.;Wang,X.;Qian, D. Z.;Sears, R. C.;Xiao, X.*"Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription withEfficacious in Vivo Anticancer Activity" JMed. Chem., 2015, 58, 5075–5087. (Highlighted in Biocentury Innovations (formerly SciBX), Labbase News)


xiao 1


2.
    
Kang, X.; Lu, Z.; Cui, C.; Fan, Y.; Dong, B.; Han, X.; Xie, X.; Tyner, J. W.; Coligan, J. E.; Collins, R. H.; Xiao, X.; You, J. M.; Zhang, C. C. “The ITIM-containing receptor LAIR1 is essential for acute myeloid leukemia development” Nat. Cell Biol., 2015, 17, 665-677 (Highlighted in UT Southwestern News, ScienceDaily, MedicalXpress, Bionews-TX, Biocentury Innovations (formerly SciBX) and BioQuick News).

xiao2


3. Chao, B.; Li, B. X.; Xiao, X.*The chemistry and pharmacology of privileged pyrroloquinazolinesMedChemComm, 2015, 6, 510-520.
xiao 5

 


4. Xie, F.; Li, B. X.; Alkayed, N. J.; Xiao, X.* “Synthesis of 14,15-EET from Arachidonic Acid Using Urea-Hydrogen Peroxide as the Oxidant” Synthetic Commun., 2015, 45, 105-110.

xiao 4



5. Li, B. X.; Xie, F.; Fan, Q.; Barnhart, K. M.; Moore, C. E.; Rheingold, A. L.; Xiao, X.* “Novel Type of Prodrug Activation through a Long-range O,N-Acyl Transfer: a Case of Water-Soluble CREB Inhibitor ” ACS Med. Chem. Lett., 2014, 5, 1104-1109.

xiao 5

 

 

 

 

 

Postdoctoral Position Available

The Xiao group at Program in Chemical Biology, Department of Physiology and Pharmacology, Knight Cancer Institute at Oregon Health & Science University (OHSU) invites outstanding applicants for a postdoctoral position in cancer chemical biology. The candidate will be part of a multidisciplinary team of investigators with expertise in drug discovery, organic synthesis, computational chemistry, biochemistry, molecular biology and cell biology. The candidate will be working in an exciting area of cancer chemical biology. Specifically, s/he will be responsible for the design, synthesis and evaluation of small molecules as novel cancer therapeutics and chemical tools to elucidate signaling mechanisms. In addition, the candidate should be capable of analyzing the data and writing up of the results into appropriate manuscript form for peer-reviewed publications. The candidate will have ample opportunities for participating grant writing, seminar presentation and other professional development. The candidate must show demonstrated capability to work within a highly collaborative environment. A Ph.D. in organic chemistry, medicinal chemistry or other related discipline is required. Salary will be competitive ($47,484 and up). Highly motivated individuals should send their current CV and names and contact information of three references to: Prof. Xiangshu Xiao, Ph.D. by email xiaoxi@ohsu.edu. OHSU is an equal opportunity, affirmative action institution.

CONTACT INFORMATION


Department of Physiology and Pharmacology
Knight Cancer Institute
Oregon Health & Science University
3181 SW Sam Jackson Park Rd
Portland, OR  97239
Phone: (503) 494-4748